Powered by

Dragonfly Therapeutics Adds World-Leading Cancer Immunotherapy Pioneer to its Scientific Advisory Board

Aug 06, 2019 - PR Newswire
Board and Executive Moves

PR Newswire

Dr. Alan Korman, renowned for his work leading to the development the first approved checkpoint inhibitor cancer therapies, joins Dragonfly's scientific team.

 Dragonfly Therapeutics, Inc. ("Dragonfly") today announced the addition of world-leading cancer immunotherapy pioneer Dr. Alan Korman to its Scientific Advisory Board.  Dr. Korman's renowned work at BMS and Medarex led to the development of two of the first approved cancer immunotherapy drugs, ipilimumab (anti-CT...